Zhaoke Hefei was honored with the 2024 “New Force Enterprise” of Hefei High-tech Zone

Zhaoke Hefei was honored with the 2024 “New Force Enterprise” of Hefei High-tech Zone

Recently, the list of the 2024 “New Force Enterprises” of Hefei High-tech Zone was announced. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke- Hefei”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, stock code: 00950), was successfully recognized as “New Force Enterprise” for its outstanding performance in technological innovation, industrial influence, and new […]

The Group’s product Treprostinil Injection featured in the “2024 New Technologies, New Products, and New Models List in Hefei”

The Group’s product Treprostinil Injection featured in the “2024 New Technologies, New Products, and New Models List in Hefei”

Recently, the Hefei Science and Technology Bureau of Anhui Province announced the proposed list of “New Technologies, New Products, and New Models in Hefei for 2024.” After rounds of selection, the Treprostinil Injection, a product of Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke Hefei”), which is a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” […]

Lee’s Pharm participated in the 12th China Cervical Cancer Prevention and Control Conference, and won “Social Responsibility Award”

Lee’s Pharm participated in the 12th China Cervical Cancer Prevention and Control Conference, and won “Social Responsibility Award”

The 12th China Cervical Cancer Prevention and Control Academic Annual Conference, hosted by the China Cervical Cancer Prevention and Control Engineering Committee, was successfully held in Chongqing from 17-20 October 2024. The conference aimed to standardize diagnosis and treatment pathways and achieve precise diagnosis and management for cervical cancer. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke […]

Lee’s Pharm participated in BIOHK2024, focusing on rare disease drug innovation

Lee’s Pharm participated in BIOHK2024, focusing on rare disease drug innovation

The Hong Kong International Biotechnology Forum and Exhibition (BIOHK2024), organized by the Hong Kong Biotechnology Organization, was successfully held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 11-14 September 2024. It is one of Asia’s largest international biotechnology conventions which aims to facilitate the exchange of ideas among international industry players and foster […]

The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched

The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched

May 30, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) grandly held the launch ceremony at its Guangzhou Nansha site for its new product Adapalene and Clindamycin Hydrochloride Gel. The Group’s Managing Director, Ms. Wanee Leelalertsuphakun, and staff members of different departments were present at the event to jointly witness the start […]

The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

Recently, the “Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns” organized by the Shanghai Caritas Foundation took place at the Guangzhou Southern Airlines Pearl Airport Hotel. During the conference, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) held a launch event for its new rare disease products, Nitric Oxide for […]

thThai